Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Qiagen N.V.
  6. News
  7. Summary
    QGEN   NL0012169213

QIAGEN N.V.

(QGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

QIAGEN Launches CE-marked Version of QuantiFERON® SARS-CoV-2 to Assess T-cell Response to COVID-19

12/02/2021 | 01:11am EST

  • Easy-to-use workflow can detect T-cell response early in the course of COVID-19 infection or following vaccination
  • Detection of T-cells can provide vital insights that completes the picture of SARS-CoV-2 immune response – beyond serology alone
  • Cell-mediated immunity can also be assessed in individuals who have been vaccinated

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the CE marking of its QuantiFERON® SARS-CoV-2 assay that measures T-cell responses to SARS-CoV-2 and aids in the assessment of immunity in individuals who have received COVID-19 vaccination.

COVID-19 vaccines stimulate the body to produce antibodies and activate T-cells to fight a SARS-CoV-2 infection. Serology tests, which measure the antibodies, often generate positive test results after vaccination but are unable to assess cellular responses. The QuantiFERON® SARS-CoV-2 assay detects CD4+ and CD8+ T-cell responses, thereby enabling a much more comprehensive assessment of immunity generated by COVID-19 vaccines.

The QuantiFERON® SARS-CoV-2 assay is based on QIAGEN’s QuantiFERON® interferon gamma release technology, which is globally recognized as an easy-to-use T-cell assay that employs whole blood and – unlike other T-cell assays – does not require the purification of lymphocytes for T-cell measurement.

“T-cells provide valuable insights into our immune system’s response to COVID-19,” said Jean-Pascal Viola, Senior Vice President and Head of the Molecular Diagnostics Business Area at QIAGEN. “The more we know about this epidemic, the better equipped the world will be to address this threat that will stay with us,” he said. “We are excited about our QuantiFERON technology enabling the assessment of immune responses that are crucial for the prevention and management of the disease.”

T-cell response to SARS-CoV-2 declines much more slowly than antibody response and may indicate how severe the course of an illness triggered by SARS-CoV-2 will be in infected patients, and how immune those are who have recovered many months – possibly even years – after having been infected.

Further information on the product can be found at here.

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). As of September 30, 2021, QIAGEN employed approximately 6,000 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).

Category: Corporate

Source: QIAGEN N.V.


© Business Wire 2021
All news about QIAGEN N.V.
01/21QIAGEN N : Earnings Document
PU
01/19Qiagen N.V Launched Higher on M&A Chatter
MT
01/19QIAGEN N : supports young biotechnology and pharma companies by announcing winners of firs..
PU
01/19QIAGEN N.V. to release results for Q4 2021 and Full-Year of 2021
BU
01/18QIAGEN Launches QIAwave Portfolio of Environmentally Friendly Products
BU
01/18QIAGEN Launches QIAwave Portfolio of Environmentally Friendly Products
CI
01/18DZ Bank Upgrades Qiagen to Buy from Hold, Raises Price Target to $59.34 From $55.79
MT
01/17ANALYST RECOMMENDATIONS : Admiral, Hiscox, National Grid, Qiagen, Unilever...
01/17QIAGEN NV : DZ Bank takes a positive view
MD
01/13QIAGEN N : liquid-based sample-prep-and-detection kit helps labs ramp up COVID testing cap..
PU
More news
Analyst Recommendations on QIAGEN N.V.
More recommendations
Financials (USD)
Sales 2021 2 198 M - -
Net income 2021 473 M - -
Net Debt 2021 941 M - -
P/E ratio 2021 23,3x
Yield 2021 -
Capitalization 11 054 M 11 054 M -
EV / Sales 2021 5,46x
EV / Sales 2022 5,62x
Nbr of Employees 6 000
Free-Float 97,8%
Chart QIAGEN N.V.
Duration : Period :
Qiagen N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QIAGEN N.V.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 48,69 $
Average target price 57,79 $
Spread / Average Target 18,7%
EPS Revisions
Managers and Directors
Thierry Bernard Chief Executive Officer & Managing Director
Roland Sackers Vice President-Finance
Lawrence A. Rosen Chairman-Supervisory Board
Barthold Piening Senior Vice President & Head-Global Operations
Metin Colpan Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
QIAGEN N.V.-10.81%11 054
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508